January 4, 2021
Via: BioSpaceAmbrx announced that the U.S. Food and Drug Administration (FDA) granted ARX788 Fast Track Designation as monotherapy for the treatment of advanced or metastatic HER2-positive breast cancer patients who have received one or more prior anti-HER2 based regimens in the […]
September 19, 2023
September 14, 2023
September 7, 2023
September 5, 2023
September 1, 2023
September 14, 2023
August 30, 2023
September 20, 2023